Savara’s Blog

Dear Shareholders, After wrapping up our three-part series on autoimmune pulmonary alveolar proteinosis (aPAP) that provided perspectives on the disease... Read More

Dear Shareholders, Our last two blog entries focused on the rare lung disease autoimmune pulmonary alveolar proteinosis (aPAP). Treatment of... Read More

Dear Shareholders, The last entry we posted was written by guest blogger, Dr. Bruce Trapnell.  He provided a physician’s perspective... Read More

Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein ―Bruce Trapnell, M.D. Autoimmune pulmonary alveolar proteinosis (aPAP) is... Read More

Dear Shareholders, Today is February 28, Rare Disease Day, which is focused on raising awareness about the prevalence and impact... Read More

Dear Shareholders, With 2018 coming to a close, it’s a good time to look back and reflect on Savara’s progress... Read More

Dear Shareholders, As we head into the summer, I’m excited to highlight some of our key recent accomplishments as well... Read More

Dear Shareholders, Today marks the 10th anniversary of Rare Disease Day, a day dedicated to raising awareness about the dire... Read More

Dear Shareholders, For Savara, 2017 was a transformative year with notable corporate achievements on our journey of building Savara into... Read More

Dear Stockholders, It has been an incredibly productive third quarter for Savara on several fronts. We have continued to execute... Read More

Dear Stockholders, As you may have seen, yesterday we announced that we will be presenting at the Rodman & Renshaw... Read More

Dear Stockholders, First, we would like to thank you for your continued interest and support in Savara. We see Savara... Read More

Special Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX – March 16, 2017 –... Read More

Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled... Read More

Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More

Strengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty... Read More

Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty... Read More

New York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More

Savara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its... Read More

Savara signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference to earlier... Read More

Preparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX –... Read More

Trial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 Savara Pharmaceuticals announced today positive... Read More